<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Thrombophilia | Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Overview of Hypercoagulable States (Thrombophilia)  Definition: A group of inherited or acquired conditions that increase the risk of developing thrombosis (blood clots) Pathophysiology:...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Thrombophilia | Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="Overview of Hypercoagulable States (Thrombophilia)  Definition: A group of inherited or acquired conditions that increase the risk of developing thrombosis (blood clots) Pathophysiology:...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Thrombophilia | Hematology">
<meta name="twitter:description" content="Overview of Hypercoagulable States (Thrombophilia)  Definition: A group of inherited or acquired conditions that increase the risk of developing thrombosis (blood clots) Pathophysiology:...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><!-- Google tag (gtag.js) --><script async src="https://www.googletagmanager.com/gtag/js?id=G-JERRQQFPF4"></script><script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-JERRQQFPF4');
    </script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="" href="aml.html">AML</a></li>
<li><a class="" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="" href="plasma-cell.html">Plasma Cell</a></li>
<li class="book-part">Platelets</li>
<li><a class="" href="plt-production.html">PLT Production</a></li>
<li><a class="" href="plt-function.html">PLT Function</a></li>
<li><a class="" href="plt-destruction.html">PLT Destruction</a></li>
<li><a class="" href="quantitative.html">Quantitative</a></li>
<li><a class="" href="thrombocytopenia-1.html">Thrombocytopenia</a></li>
<li><a class="" href="destruction.html">Destruction</a></li>
<li><a class="" href="production.html">Production</a></li>
<li><a class="" href="pseudo.html">Pseudo</a></li>
<li><a class="" href="thrombocytosis.html">Thrombocytosis</a></li>
<li><a class="" href="qualitative.html">Qualitative</a></li>
<li><a class="" href="von-willebrand.html">von Willebrand</a></li>
<li><a class="" href="bernard-soulier.html">Bernard-Soulier</a></li>
<li><a class="" href="glanzmann.html">Glanzmann</a></li>
<li class="book-part">Laboratory</li>
<li><a class="" href="cell-counts.html">Cell Counts</a></li>
<li><a class="" href="manual.html">Manual</a></li>
<li><a class="" href="automated.html">Automated</a></li>
<li><a class="" href="retics.html">Retics</a></li>
<li><a class="" href="differentials.html">Differentials</a></li>
<li><a class="" href="morphologies.html">Morphologies</a></li>
<li><a class="" href="hemoglobin.html">Hemoglobin</a></li>
<li><a class="" href="quantitative-1.html">Quantitative</a></li>
<li><a class="" href="qualitative-1.html">Qualitative</a></li>
<li><a class="" href="electrophoresis.html">Electrophoresis</a></li>
<li><a class="" href="hplc.html">HPLC</a></li>
<li><a class="" href="sickle-solubility.html">Sickle Solubility</a></li>
<li><a class="" href="hematocrit.html">Hematocrit</a></li>
<li><a class="" href="indices.html">Indices</a></li>
<li><a class="" href="hemolysis.html">Hemolysis</a></li>
<li><a class="" href="special-stains.html">Special Stains</a></li>
<li><a class="" href="other-studies.html">Other Studies</a></li>
<li><a class="" href="esr.html">ESR</a></li>
<li><a class="" href="g6pd.html">G6PD</a></li>
<li><a class="" href="heinz-body.html">Heinz Body</a></li>
<li><a class="" href="flow-cytometry.html">Flow Cytometry</a></li>
<li><a class="" href="leukemia.html">Leukemia</a></li>
<li><a class="" href="lymphoma.html">Lymphoma</a></li>
<li><a class="" href="lymphocyte-subsets.html">Lymphocyte Subsets</a></li>
<li><a class="" href="pnh.html">PNH</a></li>
<li><a class="" href="molecularcytogenetic.html">Molecular/Cytogenetic</a></li>
<li><a class="" href="recurring-abnormalities.html">Recurring Abnormalities</a></li>
<li><a class="" href="bcrabl1.html">BCR/ABL1</a></li>
<li><a class="" href="jak2.html">JAK2</a></li>
<li class="book-part">Hemostasis</li>
<li><a class="" href="coagulation-pathways.html">Coagulation Pathways</a></li>
<li><a class="" href="fibrinolytic-pathways.html">Fibrinolytic Pathways</a></li>
<li><a class="" href="vascular-system.html">Vascular System</a></li>
<li><a class="" href="disorders.html">Disorders</a></li>
<li><a class="" href="factor-deficiencies.html">Factor Deficiencies</a></li>
<li><a class="" href="hereditary.html">Hereditary</a></li>
<li><a class="" href="acquired.html">Acquired</a></li>
<li><a class="" href="inhibitors.html">Inhibitors</a></li>
<li><a class="" href="fibrinolytic.html">Fibrinolytic</a></li>
<li><a class="active" href="thrombophilia.html">Thrombophilia</a></li>
<li><a class="" href="dic.html">DIC</a></li>
<li><a class="" href="laboratory.html">Laboratory</a></li>
<li><a class="" href="ptinr.html">PT/INR</a></li>
<li><a class="" href="aptt.html">APTT</a></li>
<li><a class="" href="fibrinogen.html">Fibrinogen</a></li>
<li><a class="" href="d-dimer.html">D-dimer</a></li>
<li><a class="" href="thrombin-time.html">Thrombin Time</a></li>
<li><a class="" href="mixing-studies-1.html">Mixing Studies</a></li>
<li><a class="" href="factor-assays.html">Factor Assays</a></li>
<li><a class="" href="inhibitor-assays.html">Inhibitor Assays</a></li>
<li><a class="" href="von-willebrand-assays.html">von Willebrand Assays</a></li>
<li><a class="" href="platelet-function.html">Platelet Function</a></li>
<li><a class="" href="platelet-aggregation.html">Platelet Aggregation</a></li>
<li><a class="" href="thromboelastography.html">Thromboelastography</a></li>
<li><a class="" href="hypercoagulability.html">Hypercoagulability</a></li>
<li><a class="" href="assays.html">Assays</a></li>
<li><a class="" href="antiphospholipids.html">Antiphospholipids</a></li>
<li><a class="" href="protein-c.html">Protein C</a></li>
<li><a class="" href="protein-s.html">Protein S</a></li>
<li><a class="" href="molecular.html">Molecular</a></li>
<li><a class="" href="fv-leiden.html">FV Leiden</a></li>
<li><a class="" href="pt-20210.html">PT 20210</a></li>
<li><a class="" href="anti-xa.html">Anti-Xa</a></li>
<li><a class="" href="thrombin-inhibitors.html">Thrombin Inhibitors</a></li>
<li><a class="" href="heparin-neutralization.html">Heparin Neutralization</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Hematology">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="thrombophilia" class="section level1 unnumbered">
<h1>Thrombophilia<a class="anchor" aria-label="anchor" href="#thrombophilia"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-hypercoagulable-states-thrombophilia" class="section level2 unnumbered">
<h2>
<strong>Overview of Hypercoagulable States (Thrombophilia)</strong><a class="anchor" aria-label="anchor" href="#overview-of-hypercoagulable-states-thrombophilia"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A group of inherited or acquired conditions that increase the risk of developing thrombosis (blood clots)</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Alterations in the balance between procoagulant and anticoagulant factors in the blood</li>
<li>Increased thrombin generation and decreased fibrinolysis</li>
</ul>
</li>
<li>
<strong>Classification:</strong>
<ul>
<li>Inherited (Genetic) Thrombophilias: Caused by genetic mutations affecting coagulation factors or natural anticoagulants</li>
<li>Acquired Thrombophilias: Caused by external factors that alter the coagulation system</li>
</ul>
</li>
<li>
<strong>Clinical Significance:</strong> Increased risk of venous and/or arterial thrombosis
<ul>
<li>Deep vein thrombosis (DVT)</li>
<li>Pulmonary embolism (PE)</li>
<li>Stroke</li>
<li>Myocardial infarction</li>
<li>Recurrent pregnancy loss</li>
</ul>
</li>
</ul>
</div>
<div id="virchows-triad" class="section level2 unnumbered">
<h2>
<strong>Virchow’s Triad</strong><a class="anchor" aria-label="anchor" href="#virchows-triad"><i class="fas fa-link"></i></a>
</h2>
<p>Virchow’s triad describes the three broad categories of factors that contribute to thrombosis:</p>
<ul>
<li>
<strong>Hypercoagulability:</strong> Increased tendency to clot due to inherited or acquired abnormalities in the coagulation system</li>
<li>
<strong>Hemodynamic Changes (Stasis or Turbulence):</strong> Altered blood flow, such as occurs with prolonged immobility or atrial fibrillation</li>
<li>
<strong>Endothelial Injury:</strong> Damage to the blood vessel wall, exposing subendothelial collagen and tissue factor</li>
</ul>
</div>
<div id="inherited-thrombophilias-genetic" class="section level2 unnumbered">
<h2>
<strong>Inherited Thrombophilias (Genetic)</strong><a class="anchor" aria-label="anchor" href="#inherited-thrombophilias-genetic"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Factor V Leiden Mutation:</strong>
<ul>
<li>
<strong>Definition:</strong> The most common inherited thrombophilia; caused by a point mutation in the <em>F5</em> gene, which encodes Factor V</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Mutation: A single nucleotide change (G to A) at position 1691 in the <em>F5</em> gene, resulting in a glutamine (Q) to arginine (R) substitution at position 506 (FV R506Q)</li>
<li>Resistance to Activated Protein C (APC): The Factor V Leiden mutation makes Factor V resistant to inactivation by activated protein C (APC), a natural anticoagulant</li>
<li>Increased Thrombin Generation: Prolonged activity of Factor V leads to increased thrombin generation and a prothrombotic state</li>
</ul>
</li>
<li>
<strong>Inheritance:</strong> Autosomal dominant
<ul>
<li>Heterozygous: One copy of the mutated gene (increased risk of thrombosis)</li>
<li>Homozygous: Two copies of the mutated gene (higher risk of thrombosis)</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Increased risk of venous thrombosis (DVT, PE)</li>
<li>Increased risk of recurrent pregnancy loss</li>
<li>The risk of thrombosis is higher in individuals with Factor V Leiden who also have other risk factors (e.g., oral contraceptives, pregnancy, surgery)</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Activated Protein C (APC) Resistance Assay:
<ul>
<li>Prolonged aPTT with normal plasma</li>
<li>aPTT does not prolong with APC</li>
</ul>
</li>
<li>Factor V Leiden Mutation Analysis:
<ul>
<li>Confirms the presence of the Factor V Leiden mutation (DNA testing)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Anticoagulation:
<ul>
<li>Warfarin (Coumadin)</li>
<li>Direct oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran</li>
</ul>
</li>
<li>Prophylactic Anticoagulation:
<ul>
<li>May be considered in high-risk situations (e.g., surgery, pregnancy)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Prothrombin G20210A Mutation:</strong>
<ul>
<li>
<strong>Definition:</strong> The second most common inherited thrombophilia; caused by a point mutation in the <em>F2</em> gene, which encodes prothrombin (Factor II)</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Mutation: A single nucleotide change (G to A) at position 20210 in the 3’-untranslated region of the <em>F2</em> gene</li>
<li>Increased Prothrombin Levels: Leads to increased prothrombin mRNA stability and increased prothrombin production</li>
<li>Increased Thrombin Generation: Elevated prothrombin levels result in increased thrombin generation and a prothrombotic state</li>
</ul>
</li>
<li>
<strong>Inheritance:</strong> Autosomal dominant
<ul>
<li>Heterozygous: One copy of the mutated gene</li>
<li>Homozygous: Two copies of the mutated gene</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Increased risk of venous thrombosis (DVT, PE)</li>
<li>Increased risk of arterial thrombosis (stroke, myocardial infarction)</li>
<li>Increased risk of recurrent pregnancy loss</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Prothrombin G20210A Mutation Analysis:
<ul>
<li>Confirms the presence of the prothrombin G20210A mutation (DNA testing)</li>
</ul>
</li>
<li>Prothrombin Level: May be elevated</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Anticoagulation:
<ul>
<li>Warfarin (Coumadin)</li>
<li>Direct oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran</li>
</ul>
</li>
<li>Prophylactic Anticoagulation:
<ul>
<li>May be considered in high-risk situations (e.g., surgery, pregnancy)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Protein C Deficiency:</strong>
<ul>
<li>
<strong>Definition:</strong> Inherited deficiency of protein C, a natural anticoagulant</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Protein C: A vitamin K-dependent serine protease that is activated by the thrombin-thrombomodulin complex</li>
<li>Activated Protein C (APC): Degrades Factors Va and VIIIa, inhibiting thrombin generation</li>
<li>Protein C Deficiency: Reduces the ability to inactivate Factors Va and VIIIa, leading to a prothrombotic state</li>
</ul>
</li>
<li>
<strong>Inheritance:</strong> Autosomal dominant or autosomal recessive (more severe)</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Venous thrombosis (DVT, PE)</li>
<li>Warfarin-induced skin necrosis: A rare but serious complication that can occur when starting warfarin therapy in patients with severe protein C deficiency</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Protein C Activity Assay: Decreased protein C activity level</li>
<li>Protein C Antigen Assay: May be decreased or normal, depending on the type of deficiency</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Anticoagulation:
<ul>
<li>Warfarin (Coumadin)
<ul>
<li>Start with caution due to the risk of warfarin-induced skin necrosis</li>
<li>Overlap with a parenteral anticoagulant (e.g., heparin or low-molecular-weight heparin) is recommended when starting warfarin</li>
</ul>
</li>
<li>Direct oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran</li>
</ul>
</li>
<li>Prophylactic Anticoagulation:
<ul>
<li>May be considered in high-risk situations (e.g., surgery, pregnancy)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Protein S Deficiency:</strong>
<ul>
<li>
<strong>Definition:</strong> Inherited deficiency of protein S, a cofactor for activated protein C (APC)</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Protein S: A vitamin K-dependent protein that acts as a cofactor for APC in the inactivation of Factors Va and VIIIa</li>
<li>Protein S Deficiency: Reduces the ability of APC to inhibit thrombin generation, leading to a prothrombotic state</li>
</ul>
</li>
<li>
<strong>Inheritance:</strong> Autosomal dominant</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Venous thrombosis (DVT, PE)</li>
<li>Arterial thrombosis (less common)</li>
<li>Recurrent pregnancy loss</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Protein S Activity Assay: Decreased protein S activity level</li>
<li>Protein S Antigen Assays:
<ul>
<li>Total Protein S: Measures the total amount of protein S</li>
<li>Free Protein S: Measures the amount of protein S that is not bound to C4b-binding protein</li>
</ul>
</li>
<li>Interpreting Protein S Assays:
<ul>
<li>Protein S activity and free protein S antigen levels are most reliable for diagnosis</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Anticoagulation:
<ul>
<li>Warfarin (Coumadin)
<ul>
<li>Start with caution due to the risk of warfarin-induced skin necrosis</li>
<li>Overlap with a parenteral anticoagulant (e.g., heparin or low-molecular-weight heparin) is recommended when starting warfarin</li>
</ul>
</li>
<li>Direct oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran</li>
</ul>
</li>
<li>Prophylactic Anticoagulation:
<ul>
<li>May be considered in high-risk situations (e.g., surgery, pregnancy)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Antithrombin Deficiency:</strong>
<ul>
<li>
<strong>Definition:</strong> Inherited deficiency of antithrombin (AT), a natural anticoagulant</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Antithrombin: A serine protease inhibitor (serpin) that inhibits thrombin and other coagulation factors (Factors IXa, Xa, XIa, XIIa)</li>
<li>Antithrombin Deficiency: Reduces the ability to inhibit thrombin and other coagulation factors, leading to a prothrombotic state</li>
</ul>
</li>
<li>
<strong>Inheritance:</strong> Autosomal dominant</li>
<li>
<strong>Types:</strong>
<ul>
<li>Type I: Quantitative deficiency (reduced production of antithrombin)</li>
<li>Type II: Qualitative deficiency (dysfunctional antithrombin molecule)</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Venous thrombosis (DVT, PE)</li>
<li>Arterial thrombosis (less common)</li>
<li>Resistance to heparin therapy</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Antithrombin Activity Assay: Decreased antithrombin activity level</li>
<li>Antithrombin Antigen Assay: May be decreased or normal, depending on the type of deficiency</li>
<li>Heparin-Induced Thrombocytopenia (HIT) Testing: May be necessary to rule out HIT, as heparin resistance is a common feature</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Anticoagulation:
<ul>
<li>Warfarin (Coumadin): Higher doses of warfarin may be required to achieve therapeutic anticoagulation</li>
<li>Direct thrombin inhibitors (e.g., argatroban, bivalirudin): May be used in patients with heparin resistance or HIT</li>
</ul>
</li>
<li>Prophylactic Anticoagulation:
<ul>
<li>May be considered in high-risk situations (e.g., surgery, pregnancy)</li>
</ul>
</li>
<li>Antithrombin Concentrates:
<ul>
<li>Used for prophylaxis or treatment of acute thrombotic events, especially during surgery or pregnancy</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="acquired-thrombophilias" class="section level2 unnumbered">
<h2>
<strong>Acquired Thrombophilias</strong><a class="anchor" aria-label="anchor" href="#acquired-thrombophilias"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Antiphospholipid Syndrome (APS):</strong>
<ul>
<li>
<strong>Definition:</strong> An acquired autoimmune disorder characterized by thrombosis (arterial or venous) and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL)</li>
<li>
<strong>Antibodies:</strong>
<ul>
<li>Lupus Anticoagulant (LA)</li>
<li>Anticardiolipin Antibodies (aCL)</li>
<li>Anti-β2 Glycoprotein I Antibodies (anti-β2GPI)</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Antiphospholipid Antibodies: Bind to phospholipids and phospholipid-binding proteins, interfering with coagulation and platelet function</li>
<li>Thrombosis: In vivo, aPL can promote thrombosis through mechanisms involving:
<ul>
<li>Activation of endothelial cells and platelets</li>
<li>Inhibition of natural anticoagulant pathways (e.g., protein C pathway)</li>
<li>Complement activation</li>
</ul>
</li>
<li>Pregnancy Morbidity: aPL can interfere with placental development and function, leading to pregnancy loss</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Thrombosis:
<ul>
<li>Deep vein thrombosis (DVT)</li>
<li>Pulmonary embolism (PE)</li>
<li>Stroke</li>
<li>Myocardial infarction</li>
</ul>
</li>
<li>Pregnancy Morbidity:
<ul>
<li>Recurrent pregnancy loss (especially in the second or third trimester)</li>
<li>Preeclampsia</li>
<li>Placental insufficiency</li>
</ul>
</li>
<li>Other Manifestations:
<ul>
<li>Thrombocytopenia</li>
<li>Livedo reticularis (a mottled skin rash)</li>
<li>Cardiac valve abnormalities</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Lupus Anticoagulant (LA):
<ul>
<li>Prolonged aPTT that does not correct on mixing with normal plasma</li>
<li>Phospholipid-dependent coagulation assays (e.g., dRVVT, SCT) are prolonged and do not correct with the addition of phospholipid</li>
</ul>
</li>
<li>Anticardiolipin Antibodies (aCL):
<ul>
<li>Increased levels of IgG and/or IgM aCL antibodies</li>
</ul>
</li>
<li>Anti-β2 Glycoprotein I Antibodies (anti-β2GPI):
<ul>
<li>Increased levels of IgG and/or IgM anti-β2GPI antibodies</li>
</ul>
</li>
<li>Persistent Positivity: aPL must be present on two or more occasions, at least 12 weeks apart, to meet the laboratory criteria for APS</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Anticoagulation:
<ul>
<li>Warfarin (Coumadin) is the traditional anticoagulant</li>
<li>Direct oral anticoagulants (DOACs): Rivaroxaban, apixaban, edoxaban, dabigatran - may be used in some patients, but caution should be used</li>
</ul>
</li>
<li>Antiplatelet Therapy:
<ul>
<li>Low-dose aspirin may be used in some patients, especially those with arterial thrombosis</li>
</ul>
</li>
<li>Management of Obstetric APS:
<ul>
<li>Low-dose aspirin and prophylactic heparin during pregnancy to prevent recurrent pregnancy loss</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Acquired Antithrombin Deficiency</strong>
<ul>
<li>Reduced levels can be seen in patients with:
<ul>
<li>Nephrotic syndrome (loss of antithrombin in urine)</li>
<li>Disseminated intravascular coagulation (DIC)</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="general-laboratory-tests-for-thrombophilia" class="section level2 unnumbered">
<h2>
<strong>General Laboratory Tests for Thrombophilia</strong><a class="anchor" aria-label="anchor" href="#general-laboratory-tests-for-thrombophilia"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT):</strong> Used as screening tests to detect abnormalities in the coagulation pathways</li>
<li>
<strong>Mixing Studies:</strong> To differentiate factor deficiencies from factor inhibitors</li>
<li>
<strong>D-Dimer Assay:</strong> To assess for thrombotic activity</li>
<li>
<strong>Specific Assays for Inherited Thrombophilias:</strong>
<ul>
<li>Factor V Leiden Mutation Analysis</li>
<li>Prothrombin G20210A Mutation Analysis</li>
<li>Protein C Activity Assay</li>
<li>Protein S Activity and Antigen Assays</li>
<li>Antithrombin Activity and Antigen Assays</li>
</ul>
</li>
<li>
<strong>Antiphospholipid Antibody Testing:</strong>
<ul>
<li>Lupus Anticoagulant (LA) testing</li>
<li>Anticardiolipin (aCL) antibody assay</li>
<li>Anti-β2 Glycoprotein I antibody assay</li>
</ul>
</li>
</ul>
</div>
<div id="key-terms-83" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-83"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Hypercoagulable State (Thrombophilia):</strong> A condition with an increased risk of thrombosis</li>
<li>
<strong>Factor V Leiden:</strong> A common genetic mutation that causes resistance to activated protein C</li>
<li>
<strong>Prothrombin G20210A Mutation:</strong> A genetic mutation that leads to increased prothrombin levels</li>
<li>
<strong>Protein C:</strong> A vitamin K-dependent anticoagulant protein</li>
<li>
<strong>Protein S:</strong> A cofactor for activated protein C</li>
<li>
<strong>Antithrombin:</strong> A serine protease inhibitor that inhibits thrombin and other coagulation factors</li>
<li>
<strong>Antiphospholipid Syndrome (APS):</strong> An autoimmune disorder characterized by thrombosis, pregnancy morbidity, and antiphospholipid antibodies</li>
<li>
<strong>Lupus Anticoagulant (LA):</strong> An antibody that interferes with phospholipid-dependent coagulation assays</li>
<li>
<strong>Thrombosis:</strong> Formation of a blood clot inside a blood vessel</li>
<li>
<strong>Embolism:</strong> A blood clot that travels from one location to another</li>
</ul>
</div>
</div>
<!-- Scoll to TOC element -->
<script defer>
  function scroll_to_element() {
    header_height = document.getElementsByTagName('header')[0].offsetHeight/2;
    toc_element_position = document.querySelector('.book-toc > li > a.active').offsetTop;
    document.getElementsByTagName('header')[0].scrollTo(0, toc_element_position - header_height, 'smooth');
  }
  window.onload = scroll_to_element();
</script><div class="chapter-nav">
<div class="prev"><a href="fibrinolytic.html">Fibrinolytic</a></div>
<div class="next"><a href="dic.html">DIC</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#thrombophilia">Thrombophilia</a></li>
<li><a class="nav-link" href="#overview-of-hypercoagulable-states-thrombophilia">Overview of Hypercoagulable States (Thrombophilia)</a></li>
<li><a class="nav-link" href="#virchows-triad">Virchow’s Triad</a></li>
<li><a class="nav-link" href="#inherited-thrombophilias-genetic">Inherited Thrombophilias (Genetic)</a></li>
<li><a class="nav-link" href="#acquired-thrombophilias">Acquired Thrombophilias</a></li>
<li><a class="nav-link" href="#general-laboratory-tests-for-thrombophilia">General Laboratory Tests for Thrombophilia</a></li>
<li><a class="nav-link" href="#key-terms-83">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Hematology/blob/main/05-10-hemostasis-hypercoagulable-states.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Hematology/edit/main/05-10-hemostasis-hypercoagulable-states.Rmd">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-02-26 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
